PPARGC1A and cancer: To assess the therapeutic effects of inhibiting the activin A–PGC1α axis in the muscle endothelium, we first examined whether inhibition of activin A signaling using an anti-activin A neutralizing antibody could restore EC function and prevent muscle loss in cancer cachexia (Extended Data Fig. 9a).